Digital Analysis of BCL2 Expression in Laryngeal Squamous Cell Carcinoma
Autor: | Efthymios Kyrodimos, Vasileios Ragos, Vasileios Papanikolaou, Dimitrios Peschos, Evangelos Tsiambas, Aristeidis Chrysovergis |
---|---|
Rok vydání: | 2019 |
Předmět: |
Male
Larynx Cancer Research medicine.medical_treatment 03 medical and health sciences 0302 clinical medicine hemic and lymphatic diseases medicine Carcinoma Humans Laryngeal Neoplasms business.industry General Medicine medicine.disease Laryngeal squamous cell carcinoma Lymphoma Radiation therapy medicine.anatomical_structure Proto-Oncogene Proteins c-bcl-2 Oncology Apoptosis 030220 oncology & carcinogenesis Carcinoma Squamous Cell Cancer research Immunohistochemistry Female Signal transduction business |
Zdroj: | Anticancer Research. 39:1253-1257 |
ISSN: | 1791-7530 0250-7005 |
Popis: | Background Deregulation of apoptosis is critical regarding the development and progression of malignancies, including laryngeal squamous cell carcinoma (LSCC). B-Cell lymphoma 2 (BCL2) (gene locus:18q21.33), located on the outer mitochondrial membrane, acts mainly as an anti-apoptotic factor suppressing and blocking apoptotic signal transduction. Materials and methods Fifty (n=50) primary LSCC tissue sections were used. Immunohistochemistry and digital image analysis were implemented for evaluating BCL2 protein expression levels. Results High BCL2 protein expression levels were observed in 21/50 (42%) LSCC tissue sections, whereas the remaining cases (n=29) demonstrated a low expression. Overall, BCL2 expression was associated with grade (p=0.046) and anatomical region of the examined malignancies (transglottic, p=0.047). Interestingly, high BCL2 expression levels were strongly associated with radiotherapy-based only regimens (p=0.01) in corresponding patients. Conclusion BCL2 overexpression was found to be correlated with an aggressive phenotype (advanced grade of differentiation) in LSCC, also demonstrating a potential selective anatomic localization (transglotic region). Additionally, BCL2 overexpression appears to be a negative regulator for successful radiotherapy implementation by reducing the apoptotic process in patients. |
Databáze: | OpenAIRE |
Externí odkaz: |